Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-26T21:24:02.018Z Has data issue: false hasContentIssue false
  • English
  • Français

Lurasidone in adolescents with schizophrenia: Sustained remission and recovery during 2 years of open-label treatment

Published online by Cambridge University Press:  13 August 2021

M. Tocco ,
A. Pikalov ,
L. Deng  and
R. Goldman
M. Tocco*
Affiliation:
Medical Affairs, Sunovion Pharmaceuticals Inc., Marlborough, United States of America
A. Pikalov
Affiliation:
Medical Affairs, Sunovion Pharmaceuticals Inc., Marlborough, United States of America
L. Deng
Affiliation:
Medical Affairs, Sunovion Pharmaceuticals Inc., Marlborough, United States of America
R. Goldman
Affiliation:
Medical Affairs, Sunovion Pharmaceuticals Inc., Marlborough, United States of America Medical Affairs, Sunovion Pharmaceuticals Inc, Fort Lee, United States of America
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Compared with adult onset, early onset schizophrenia is typically characterized by greater illness severity and less favorable prognosis.

Objectives

To evaluate the proportion of adolescent patients with schizophrenia who achieved sustained remission and recovery during 2 years of treatment with lurasidone.

Methods

Patients aged 13-17 years with a DSM-IV-TR diagnosis of schizophrenia, and a Positive and Negative Symptom Scale (PANSS) total score ≥70 and <120, were randomized to 6 weeks of double-blind (DB), fixed-dose treatment with lurasidone (37 or 74 mg/d) or placebo. Patients who completed 6 weeks of DB treatment were eligible to enroll in a 2-year, open-label (OL), flexible dose extension study of lurasidone (18.5-74 mg/d). Criteria for sustained remission, were the 6-month consensus criteria summarized by Andreasen (Am J Psych 2005;162:441-9). Criteria for sustained recovery consisted of meeting sustained remission criteria with a Children’s Global Assessment Scale (CGAS) score ≥70 for at least 6-months indicating no clinically significant functional impairment.

Results

A total of 271 patients completed the 6-week DB study and entered the extension study, and 186 (68.6%) and 156 (57.6%) completed 52 weeks and 104 weeks of treatment, respectively. During OL treatment with lurasidone, 52.8% met sustained remission criteria, with a Kaplan-Meier (KM) estimate of 64.1 weeks for median time to sustained remission; and 28.8% met sustained recovery criteria, KM estimate of 104.6 weeks for median time to sustained recovery.

Conclusions

For adolescents with schizophrenia, treatment with lurasidone was associated with high rates of sustained remission and sustained recovery over a two-year period.

Disclosure

Employee of Sunovion Pharmaceuticals Inc. The study summarized in this Abstract was supported by funding from Sunovion Pharmaceuticals Inc

Keywords

lurasidoneremissionschizophréniaadolescence
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S165 - S166
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.